Growth and Syndromes

Scientific Programme, ePosters & Abstracts

Previous issue | Volume 98 | ESPE2024

62nd Annual ESPE (ESPE 2024)

Liverpool, UK
16 Nov 2024 - 18 Nov 2024

The 62nd ESPE Annual Meeting will now be taking place in Liverpool, UK.

Free Communications

Previous section
Adrenals and HPA Axis 1

Table of contents

Next section
Fat, Metabolism and Obesity 1

hrp0098fc5.1 | Growth and Syndromes

A homozygous variant in ZSWIM6 causes short stature, microcephaly and developmental delay

hrp0098fc5.2 | Growth and Syndromes

The pathogenesis of Noonan syndrome and associated growth restriction is modulated by NOC2L, a novel interactor of LZTR1 leading to impaired p53 signalling

hrp0098fc5.3 | Growth and Syndromes

Gene expression of monosomy × during human development reveals potential mechanisms in Turner syndrome

hrp0098fc5.4 | Growth and Syndromes

Predictors of short stature at age 6-7 years in Israeli children

hrp0098fc5.5 | Growth and Syndromes

Phase 2 Trial of Vosoritide Use in patients with Hypochondroplasia: Pharmacokinetic/ Pharmacodynamic analysis from 12 Month Data

hrp0098fc5.6 | Growth and Syndromes

First line treatment evaluation in patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD): Data from the Global Increlex^® Registry

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more

ESPE Abstracts

62nd Annual ESPE (ESPE 2024)

Free Communications

Growth and Syndromes

A homozygous variant in ZSWIM6 causes short stature, microcephaly and developmental delay

The pathogenesis of Noonan syndrome and associated growth restriction is modulated by NOC2L, a novel interactor of LZTR1 leading to impaired p53 signalling

Gene expression of monosomy × during human development reveals potential mechanisms in Turner syndrome

Predictors of short stature at age 6-7 years in Israeli children

Phase 2 Trial of Vosoritide Use in patients with Hypochondroplasia: Pharmacokinetic/ Pharmacodynamic analysis from 12 Month Data

First line treatment evaluation in patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD): Data from the Global Increlex^® Registry

BiosciAbstracts

ESPE Abstracts

62nd Annual ESPE (ESPE 2024)

Free Communications

Growth and Syndromes

A homozygous variant in ZSWIM6 causes short stature, microcephaly and developmental delay

The pathogenesis of Noonan syndrome and associated growth restriction is modulated by NOC2L, a novel interactor of LZTR1 leading to impaired p53 signalling

Gene expression of monosomy × during human development reveals potential mechanisms in Turner syndrome

Predictors of short stature at age 6-7 years in Israeli children

Phase 2 Trial of Vosoritide Use in patients with Hypochondroplasia: Pharmacokinetic/ Pharmacodynamic analysis from 12 Month Data

First line treatment evaluation in patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD): Data from the Global Increlex® Registry

BiosciAbstracts

First line treatment evaluation in patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD): Data from the Global Increlex^® Registry